Sayfa yüklenirken bir hata oluştu.
Teknik ekibimiz bilgilendirildi, ancak sorunun devam etmesi durumunda lütfen e-posta destek widget ile bize ulaşın.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | 13,8x - 15,2x | 14,5x |
| Selected Fwd EBIT Multiple | 7,4x - 8,2x | 7,8x |
| Fair Value | $7,67 - $9,34 | $8,51 |
| Upside | -8,7% - 11,1% | 1,2% |
| Benchmarks | Ticker | Full Ticker |
| Amphastar Pharmaceuticals, Inc. | AMPH | NasdaqGS:AMPH |
| Supernus Pharmaceuticals, Inc. | SUPN | NasdaqGM:SUPN |
| ANI Pharmaceuticals, Inc. | ANIP | NasdaqGM:ANIP |
| TherapeuticsMD, Inc. | TXMD | NasdaqGS:TXMD |
| Indivior PLC | INDV | NasdaqGS:INDV |
| Amneal Pharmaceuticals, Inc. | AMRX | NasdaqGS:AMRX |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| AMPH | SUPN | ANIP | TXMD | INDV | AMRX | ||
| NasdaqGS:AMPH | NasdaqGM:SUPN | NasdaqGM:ANIP | NasdaqGS:TXMD | NasdaqGS:INDV | NasdaqGS:AMRX | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | NM- | -16.2% | -2.3% | NM- | 7.6% | NM- | |
| 3Y CAGR | 42.0% | -8.3% | NM- | NM- | 16.0% | 17.2% | |
| Latest Twelve Months | -8.0% | 941.7% | -72.3% | 55.2% | 7.5% | 18.1% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | 19.3% | 14.0% | -1.3% | -292.2% | 19.5% | 9.7% | |
| Prior Fiscal Year | 31.0% | 2.2% | 10.2% | -654.6% | 23.8% | 11.3% | |
| Latest Fiscal Year | 28.1% | 9.3% | 2.4% | -198.3% | 24.6% | 12.5% | |
| Latest Twelve Months | 26.6% | 8.8% | 2.2% | -170.2% | 24.4% | 12.9% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 2.03x | 2.36x | 2.68x | 8.08x | 1.58x | 1.83x | |
| EV / LTM EBITDA | 6.0x | 11.4x | 19.9x | -5.6x | 6.0x | 8.6x | |
| EV / LTM EBIT | 7.6x | 26.9x | 124.0x | -4.8x | 6.5x | 14.2x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | -4.8x | 7.6x | 124.0x | ||||
| Historical EV / LTM EBIT | 15.0x | 16.6x | 29.6x | ||||
| Selected EV / LTM EBIT | 13.8x | 14.5x | 15.2x | ||||
| (x) LTM EBIT | 364 | 364 | 364 | ||||
| (=) Implied Enterprise Value | 5,011 | 5,275 | 5,539 | ||||
| (-) Non-shareholder Claims * | (2,566) | (2,566) | (2,566) | ||||
| (=) Equity Value | 2,445 | 2,709 | 2,973 | ||||
| (/) Shares Outstanding | 313.4 | 313.4 | 313.4 | ||||
| Implied Value Range | 7.80 | 8.64 | 9.48 | ||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 7.80 | 8.64 | 9.48 | 8.41 | |||
| Upside / (Downside) | -7.2% | 2.8% | 12.8% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | AMPH | SUPN | ANIP | TXMD | INDV | AMRX | |
| Enterprise Value | 1,487 | 1,538 | 1,799 | 15 | 1,910 | 5,202 | |
| (+) Cash & Short Term Investments | 237 | 464 | 155 | 6 | 373 | 62 | |
| (+) Investments & Other | 6 | 0 | 0 | 0 | 27 | 24 | |
| (-) Debt | (653) | (32) | (630) | (7) | (370) | (2,580) | |
| (-) Other Liabilities | 0 | 0 | 0 | 0 | 0 | (72) | |
| (-) Preferred Stock | 0 | 0 | (25) | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 1,078 | 1,969 | 1,299 | 14 | 1,940 | 2,636 | |
| (/) Shares Outstanding | 47.1 | 62.6 | 20.0 | 11.6 | 124.8 | 313.4 | |
| Implied Stock Price | 22.86 | 31.45 | 64.91 | 1.17 | 15.55 | 8.41 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 22.86 | 31.45 | 64.91 | 1.17 | 15.55 | 8.41 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |